Sysmex (OTCMKTS:SSMXY) Shares Up 8.6% – Here’s What Happened

Shares of Sysmex Corporation ADR (OTCMKTS:SSMXY) shot up 8.6% on Monday . The company traded as high as $9.7495 and last traded at $9.7495. Approximately 422 shares were traded during trading, a decline of 100% from the average daily volume of 245,966 shares. The stock had previously closed at $8.98.

Analysts Set New Price Targets

Separately, Citigroup downgraded Sysmex from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 16th. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, Sysmex presently has a consensus rating of “Hold”.

Sysmex Stock Performance

The company has a current ratio of 3.26, a quick ratio of 2.46 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $6.01 billion, a PE ratio of 25.13 and a beta of 1.07. The firm’s fifty day moving average price is $8.78 and its 200 day moving average price is $9.09.

Sysmex (OTCMKTS:SSMXY) last posted its quarterly earnings results on Thursday, May 14th. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The firm had revenue of $877.92 million for the quarter, compared to analysts’ expectations of $862.45 million. Sysmex had a return on equity of 7.23% and a net margin of 7.13%.Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. On average, research analysts anticipate that Sysmex Corporation ADR will post 0.42 earnings per share for the current year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.